Albireo reports data on A4250 in children with biliary atresia and Alagille syndrome
Albireo Pharma announced results in Alagille syndrome and biliary atresia patients from its completed Phase 2 clinical trial evaluating A4250 in pediatric cholestasis. A4250 is a highly potent and selective inhibitor of the ileal bile acid transporter. April 13, 2019